DK1276501T3 - Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi - Google Patents

Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi

Info

Publication number
DK1276501T3
DK1276501T3 DK01928938T DK01928938T DK1276501T3 DK 1276501 T3 DK1276501 T3 DK 1276501T3 DK 01928938 T DK01928938 T DK 01928938T DK 01928938 T DK01928938 T DK 01928938T DK 1276501 T3 DK1276501 T3 DK 1276501T3
Authority
DK
Denmark
Prior art keywords
photodynamic therapy
treating tumors
tumor
bearing
treating
Prior art date
Application number
DK01928938T
Other languages
English (en)
Other versions
DK1276501T5 (da
Inventor
William C Fanslow Iii
Elaine K Thomas
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK1276501T3 publication Critical patent/DK1276501T3/da
Publication of DK1276501T5 publication Critical patent/DK1276501T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01928938T 2000-04-25 2001-04-25 Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi DK1276501T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19954500P 2000-04-25 2000-04-25
PCT/US2001/013616 WO2001080888A2 (en) 2000-04-25 2001-04-25 Method for treatment of tumors using photodynamic therapy

Publications (2)

Publication Number Publication Date
DK1276501T3 true DK1276501T3 (da) 2006-04-24
DK1276501T5 DK1276501T5 (da) 2007-02-26

Family

ID=22737985

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01928938T DK1276501T5 (da) 2000-04-25 2001-04-25 Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi

Country Status (10)

Country Link
US (2) US20020041864A1 (da)
EP (1) EP1276501B9 (da)
AT (1) ATE313334T1 (da)
AU (2) AU5574001A (da)
CA (1) CA2407336A1 (da)
DE (1) DE60116075T4 (da)
DK (1) DK1276501T5 (da)
ES (1) ES2254408T4 (da)
PT (1) PT1276501E (da)
WO (1) WO2001080888A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110846A1 (en) * 2001-01-30 2004-06-10 Beatrice Leveugle Perylenequinones for use with immunotherapy agents
IL157946A0 (en) * 2001-04-02 2004-03-28 Genentech Inc Combination therapy
AU2003226082A1 (en) * 2002-03-25 2003-11-11 The General Hospital Corporation Methods of adjuvant photodynamic therapy to enhance radiation sensitization
WO2004092195A2 (en) * 2003-04-09 2004-10-28 Administrators Of The Tulane Educational Fund Dendritic cell binding proteins and uses thereof
CA2615510A1 (en) * 2005-08-10 2007-02-15 Quest Pharmatech Inc. Perylenequinone derivatives and uses thereof
US8454991B2 (en) * 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
US20100255080A1 (en) * 2009-04-02 2010-10-07 Sesvalia Usa, Llc Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
EP2718457A4 (en) * 2011-06-06 2014-12-24 Immungene Inc GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
JP2022512540A (ja) * 2018-08-29 2022-02-07 シャタック ラボ,インコーポレイテッド Flt3l系キメラタンパク質
AU2020294700A1 (en) * 2019-06-17 2022-02-03 Renovaro Biosciences Inc. Allogeneic T-cell-based HIV vaccine to induce cellular and humoral immunity
EP4329786A1 (en) 2021-04-30 2024-03-06 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
BR112023026235A2 (pt) * 2021-06-17 2024-03-05 Kalivir Immunotherapeutics Inc Proteínas de fusão tnfsf-l e seus usos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
EP0615451B1 (en) * 1992-05-26 2005-12-07 Immunex Corporation Novel cytokine that binds cd30
JPH09507074A (ja) * 1993-12-23 1997-07-15 イミュネックス・コーポレーション Cd40を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
US6495129B1 (en) * 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
SI9620116A (sl) * 1995-10-04 1999-08-31 Immunex Corporation Stimulatorni faktor dendritičnih celic
US6146409A (en) * 1996-05-20 2000-11-14 Bergein F. Overholt Therapeutic methods and devices for irradiating columnar environments
NZ333607A (en) * 1996-07-10 2000-08-25 Immunex Corp Method of stimulating the immune system by transfecting dendritic cells
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
WO2000051638A1 (en) * 1999-02-26 2000-09-08 Qlt Phototherapeutics Inc. Photodynamic therapy in combination with apoptosis inducing factors
US6756141B2 (en) * 2001-04-17 2004-06-29 Southwest Research Institute Three-electrode fuel cell

Also Published As

Publication number Publication date
WO2001080888A3 (en) 2002-08-29
DK1276501T5 (da) 2007-02-26
CA2407336A1 (en) 2001-11-01
AU5574001A (en) 2001-11-07
DE60116075T4 (de) 2007-06-06
EP1276501B1 (en) 2005-12-21
DE60116075D1 (de) 2006-01-26
PT1276501E (pt) 2006-05-31
EP1276501B9 (en) 2007-01-24
DE60116075T2 (de) 2006-08-31
ES2254408T3 (es) 2006-06-16
AU2001255740B2 (en) 2006-03-16
EP1276501A2 (en) 2003-01-22
WO2001080888A2 (en) 2001-11-01
ES2254408T4 (es) 2007-10-01
US20050129689A1 (en) 2005-06-16
ATE313334T1 (de) 2006-01-15
US20020041864A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
NO20022065D0 (no) Terapeutisk anvendelse
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DK1276501T3 (da) Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi
WO2001082961A3 (en) Methods for treating bone tumors
DK1827500T3 (da) Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
WO2005092073A3 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
EP1605847A4 (en) PHOTODYNAMIC THERAPY PROVIDED AGAINST ANTIBODIES
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
WO2000057911A3 (en) Hapten-conjugated mammalian cells and methods of making and using thereof
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
TW200724158A (en) Combination therapy in the treatment of cancer
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
WO2005041860A3 (en) Stem cells for use in locating and targeting tumor cells
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
WO2005006947A3 (en) Cells for use in locating and targeting tumor cells
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox